Candida infections can be serious in ICU patients, as Candida is an organism that specially colonizes the digestive system. In immunocompromised patients, treatment is protocolized but in non-neutropenic patients it is not well established. On the other hand, the treatment of this type of infection is not absent of adverse effects. The prevalence of fungal infections, especially Candidiasis and its mortality in the ICU is high, mainly due to the lack of diagnosis and absence of treatment criteria, because they are often detected in the Disseminated Candidiasis phase, such as candidemia. One of the indicators of the progression of the disease is the presence of Candida in more than two different foci, named Candida Multifocality, within the concept of Invasive Candidiasis. In fact, Fundicu Project was created to optimize the management of Candidiasis. The management of Candidiasis in ICU patients first requires the identification of patients at high risk of Candidiasis, which must be performed based on the evidence of immune dysregulation, higher severity index (APACHE, MODS), long ICU stays or other factors such as mechanical ventilation or use of broad-spectrum antibiotics. In order to increase detection and dispense the appropriate anti-fungal at an early stage, it is necessary to include the concept of Multifocality in Invasive Candidiasis with screening of different foci. Anti-fungal treatment reduces mortality both overall and attributable to Candida. Detecting a high Invasive Candidiasis risk is a patient safety concept and should be treated as such. Identifying patients (critically non-neutropenic adult patients with severe MODS and the first isolation of Candida species in a study sample of possible secondary infection) and demonstrating Invasive Candidiasis (Multifocal or Disseminated) require urgent initiation of anti-fungal treatment to minimize mortality attributable to Invasive Candidiasis in ICU and eliminate mortality rates above 50%.